Aptar Q3 2026 Earnings: Sales Rise as Russia Charge Cuts GAAP Profit

AptarGroup, Inc. (NYSE: ATR) reported Q3 2026 revenue of $1.02 billion, up 6% year over year, while diluted EPS fell to $0.51 from $1.92. Adjusted EPS declined to $1.52 from $1.62 at comparable exchange rates, as the Russia deconsolidation charge and lower margins offset broad-based sales growth.

Core Financial Results

Reported sales increased 6%, while core sales—which neutralize currency effects and exclude material acquisitions and the Russian subsidiary from both periods—grew 5%. Operating income was nearly unchanged despite the higher revenue, as cost of sales and selling, research, development and administrative expenses rose faster than sales.

The difference between GAAP and adjusted earnings primarily reflected the loss of control over Aptar’s Russian subsidiary. The table separates reported results from the company’s non-GAAP measures.

The reported effective tax rate rose to 45.6% from 17.1% because the Russia deconsolidation impact was not tax-deductible. The adjusted effective tax rate was 23.4%, compared with 20.8% a year earlier.

Business and Segment Performance

All three segments generated reported and core sales growth, but each recorded a lower adjusted EBITDA margin. Closures produced the fastest growth, while Pharma’s headline core growth was restrained by the anticipated reduction in emergency medicine sales.

Pharma’s core sales increased only 1%, but the company said growth would have been 8% after adjusting for emergency medicine destocking. Demand improved across central nervous system and pulmonary therapies, nasal decongestants, eye care, dermal drug delivery, biologics, vaccines and GLP-1 therapies. Unfavorable product mix related to destocking reduced the segment’s margin, partly offsetting productivity improvements and royalty income.

Beauty benefited from prestige fragrance dispensing, color cosmetics and hair care applications. Pass-throughs of higher input costs also supported sales, but unfavorable mix and continuing operational challenges in North America weighed on profitability.

Closures’ growth was led by bottled water, concentrates, beverage dispensing products and condiments. Higher input-cost pass-throughs contributed to core sales but diluted the segment’s adjusted EBITDA margin.

Russia Deconsolidation and Mix Pressure Offset Sales Growth

Aptar deconsolidated its Russian subsidiary after a government decree placed the operation under external administration, causing the company to lose control. Aptar recorded a $58.0 million deconsolidation loss that included approximately $30.0 million of cash held by the subsidiary. Related receivable reserves and legal expenses increased the total impact to $61.2 million before tax and $60.4 million after tax, equivalent to $0.94 per diluted share.

The Russia charge explains much of the decline in GAAP earnings, but it does not fully account for the weaker underlying profitability. Operating income slipped even as revenue increased, and adjusted EBITDA margin contracted by 190 basis points. The segment results show that product mix, cost pass-throughs and operational issues also pressured margins independently of the Russia event.

Cash Flow and Balance Sheet

Aptar disclosed cash flow only for the first nine months rather than Q3 alone. Nine-month operating cash flow was $389.8 million, compared with $386.3 million a year earlier. Capital expenditures increased to $192.0 million from $183.6 million, leaving free cash flow of approximately $197.8 million under the company’s definition, versus approximately $206.0 million in the prior-year period.

Cash and equivalents declined to $204.2 million at September 30 from $402.4 million at the end of 2025. The change included $30.0 million of cash removed through the Russia deconsolidation and $357.5 million of net financing outflows. Accounts receivable increased to $883.9 million from $803.8 million, while inventory rose to $582.6 million from $537.8 million.

Short- and long-term obligations totaled approximately $1.38 billion, down from approximately $1.48 billion at year-end. During the first nine months, Aptar repaid $160.9 million of long-term obligations, repurchased $180.0 million of stock and paid $92.1 million in dividends.

The company returned $61 million to shareholders through repurchases and dividends during Q3 and $272 million during the first nine months. After the quarter, the board increased the quarterly dividend from $0.48 to $0.50 per share.

Earnings Guidance

Aptar expects Q4 adjusted EPS of $1.39 to $1.47. Management expects continued Pharma growth, particularly in consumer healthcare and injectables, without the emergency medicine destocking headwind that affected Q3. It also expects Closures’ beverage momentum to continue while focusing on improving Beauty’s North American operations.

Recent Insider Transactions

The supplied six-month insider data categorized 107,307 shares across 30 transactions as purchases and 40,716 shares across nine transactions as sales, producing net purchases of 66,591 shares. Because the detailed records include zero-price stock awards and other non-sale transactions, the aggregate should not be interpreted as open-market buying alone.

The latest individual records included the following sales. The supplied data did not specify a currency for the prices or transaction values.

These records establish the transaction activity but do not by themselves indicate insiders’ views about Aptar’s prospects.

Risks Investors Should Monitor

• Further consequences from the Russian subsidiary: Aptar has already recognized a $60.4 million after-tax impact and lost control of approximately $30.0 million of subsidiary cash. The ability to recover value from the Russian operation remains exposed to government action.
• Continued margin pressure: Overall adjusted EBITDA margin fell 190 basis points, and all three segments reported margin declines. Unfavorable product mix, input-cost pass-throughs and operating costs could continue to limit the benefit of sales growth.
• Beauty’s North American operations: Beauty delivered 8% core sales growth, but continuing challenges in North America contributed to a lower segment margin. Management’s efforts to improve the business remain an important profitability variable.
• Working-capital and liquidity demands: Receivables and inventory increased from year-end while cash declined. Although nine-month operating cash flow was stable, higher capital spending and capital returns reduced available cash.
• Guidance assumptions: The Q4 adjusted EPS range assumes a 1.12 euro-to-dollar exchange rate and a 17.5%-19.5% tax rate, making reported results sensitive to changes in currency and taxation.

Summary

Aptar’s Q3 2026 sales growth was broad-based, with Closures and Beauty leading and Pharma improving outside emergency medicine destocking. Profitability moved in the opposite direction because of the Russia deconsolidation charge, weaker segment margins and a higher tax rate. The main points to monitor are whether the expected removal of the Pharma destocking headwind supports Q4 earnings, whether Beauty’s North American operations improve and whether Aptar can convert continued revenue growth into firmer margins and cash generation.